Aptus Pharma Delivers Robust FY26 Growth, Proposes Rs 44.88 Crore Preferential Issue

Revenue from operations reached Rs 46.57 crore, up 89.65% YoY. Profit after tax grew 49.05% to Rs 4.62 crore.

Reader Takeaway: Strong growth post-listing; fundraising to fuel expansion plans.

What just happened

Aptus Pharma Ltd, in its first annual report since listing, announced a significant 89.65% year-on-year increase in revenue to Rs 46.57 crore for the fiscal year ended March 31, 2026. Profit after tax (PAT) saw a 49.05% rise, reaching Rs 4.62 crore.

The company also highlighted a completed bonus share issue of 1,02,90,000 shares in a 3:2 ratio on May 12, 2026. Furthermore, it has proposed a preferential issue of 16,02,870 equity shares at Rs 280 per share, aiming to raise approximately Rs 44.88 crore.

Why this matters

This robust financial performance in its first year as a listed entity demonstrates Aptus Pharma's operational efficiency and market traction. The proposed preferential issue signals a clear strategy for future growth, with funds earmarked for critical capital expenditures including land acquisition, plant construction, and storage facilities. This move could position the company for enhanced scale and potential international expansion.

The backstory

This is Aptus Pharma's first annual report as a publicly traded company after its listing. The company operates on an asset-light model, leveraging third-party manufacturers to expand its product portfolio, which grew to over 250 formulations by March 2026, up from 194 the previous year.

What changes now

The successful completion of the preferential issue will significantly bolster Aptus Pharma's capital base. The raised funds are intended for tangible expansion projects, which could lead to increased production capacity and broader market reach. The bonus issue has already increased the company's paid-up share capital.

Risks to watch

Investors should closely monitor the approval and execution of the preferential issue. The deployment of capital for expansion needs to translate into sustained growth. A minor regulatory issue regarding a Rs 5,000 fine for delayed disclosure was reported, with a waiver request pending.

Peer comparison

While specific peer financial data is not provided in the filing, Aptus Pharma's reported revenue growth of 89.65% indicates strong performance in the pharmaceutical formulations sector. Companies in this space often focus on expanding product portfolios and manufacturing capabilities.

Context metrics (time-bound)

• Revenue from Operations (FY 2025-26): Rs 46.57 crore (vs Rs 24.56 crore in FY 2024-25)
• Profit After Tax (FY 2025-26): Rs 4.62 crore (vs Rs 3.10 crore in FY 2024-25)
• Bonus Issue: 1,02,90,000 shares on May 12, 2026 (3:2 ratio)
• Proposed Preferential Issue: Rs 44.88 crore at Rs 280 per share

What to track next

Investors should watch for shareholder approval of the preferential issue at the 16th AGM, the subsequent capital infusion, and the progress of the planned capital expenditure projects. Monitoring the company's product portfolio expansion and any international market entries will also be key.